טרקליר 125 מג ישראל - עברית - Ministry of Health

טרקליר 125 מג

j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 125 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

טריטייס  קומפ 2.5 מג  12.5 מג ישראל - עברית - Ministry of Health

טריטייס קומפ 2.5 מג 12.5 מג

sanofi israel ltd - hydrochlorothiazide; ramipril - טבליה - ramipril 2.5 mg; hydrochlorothiazide 12.5 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

טריטייס קומפ 5 מג  25 מג ישראל - עברית - Ministry of Health

טריטייס קומפ 5 מג 25 מג

sanofi israel ltd - hydrochlorothiazide; ramipril - טבליה - ramipril 5 mg; hydrochlorothiazide 25 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

וקטור פלוס 8012.5 ישראל - עברית - Ministry of Health

וקטור פלוס 8012.5

unipharm ltd, israel - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan - valsartan - for the treatment of hypertension for patients in whom combination therapy is appropriate.

וקטור פלוס 16025 ישראל - עברית - Ministry of Health

וקטור פלוס 16025

unipharm ltd, israel - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan - valsartan - for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

וקטור פלוס 16012.5 ישראל - עברית - Ministry of Health

וקטור פלוס 16012.5

unipharm ltd, israel - hydrochlorothiazide; valsartan - טבליה - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan - valsartan - for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

פרבסטאטין טבע 10 מג ישראל - עברית - Ministry of Health

פרבסטאטין טבע 10 מג

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

פרבסטאטין טבע 20 מג ישראל - עברית - Ministry of Health

פרבסטאטין טבע 20 מג

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 20 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

אקנתרים ישראל - עברית - Ministry of Health

אקנתרים

trima israel pharmaceutical products maabarot ltd - erythromycin - תמיסה - erythromycin 2 %w/v - erythromycin - erythromycin - as a topical antibiotic treatment for all forms of acne, particularly inflamatory acne with papules and pustules.

פרימולוט-נור ישראל - עברית - Ministry of Health

פרימולוט-נור

bayer israel ltd - norethisterone acetate - טבליה - norethisterone acetate 5 mg - norethisterone - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.